French biotech company OSE Immunotherapeutics (XPAR: OSE) announced on Tuesday that it presented new data on its most advanced product, Tedopi, at the ASCO 2023 Annual Meeting.

Tedopi is an immunotherapy that activates tumour-specific T-cells and has shown positive efficacy results in non-small cell lung cancer (NSCLC) patients who have failed immune checkpoint inhibitors.

The Phase 3 clinical trial, ATALANTE-1, compared Tedopi to chemotherapy in HLA-A2+ patients with advanced NSCLC. The data analyzed prognostic factors of overall survival and demonstrated that Tedopi improved survival by controlling tumour growth, regardless of the best treatment response.

In addition, OSE Immunotherapeutics presented a poster on the ongoing Phase 2 TEDOVA clinical trial in ovarian cancer. This trial evaluates the use of Tedopi alone or in combination with pembrolizumab as maintenance therapy in platinum-sensitive recurrent ovarian cancer patients.

These results presented at ASCO 2023 support the potential of Tedopi as a promising treatment option for NSCLC patients with secondary resistance to immune checkpoint inhibitors. OSE Immunotherapeutics plans to advance the clinical development of Tedopi in second-line therapy through a confirmatory Phase 3 trial.

The company aims to address the unmet medical need in ovarian cancer by evaluating Tedopi in combination with pembrolizumab in the TEDOVA trial. This innovative approach aims to turn "immune cold" ovarian tumours into "immune hot" tumours by optimizing tumour-associated neo-epitopes.

Overall, the data presented at ASCO 2023 reinforces OSE Immunotherapeutics' commitment to developing first-in-class immuno-oncology assets, with Tedopi as its most advanced product.